{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "The present study was undertaken to examine the feasibility of assessing adjuvant statin therapy in patients with operable OAC in a phase III RCT."
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "centrally allocated (1 : 1) to simvastatin 40\u2009mg or matching placebo by block randomization, stratified by centre."
      },
      "Participants": {
        "score": 2,
        "evidence": "adults with OAC (including Siewert I\u2013II lesions) who had undergone oesophagectomy"
      },
      "Intervention": {
        "score": 2,
        "evidence": "centrally allocated (1 : 1) to simvastatin 40\u2009mg or matching placebo"
      },
      "Objective": {
        "score": 1,
        "evidence": "The present study was undertaken to examine the feasibility of assessing adjuvant statin therapy in patients with operable OAC in a phase III RCT."
      },
      "Method_Outcome": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "centrally allocated (1 : 1) to simvastatin 40\u2009mg or matching placebo by block randomization, stratified by centre."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Participants, clinicians and investigators were blinded to treatment allocation."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "A total of 120 patients were assessed for eligibility at four centres, of whom 32 (26\u00b77 per cent) were randomized, 16 in each group."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Seven patients withdrew."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Participants allocated to simvastatin had lower low\u2010density lipoprotein cholesterol levels by 3\u2009months (adjusted mean difference \u22120\u00b783 (95 per cent\u2009c.i. \u22121\u00b74 to \u22120\u00b722) mmol/l; P = 0\u00b7009)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were similar between the groups."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Registration number: ISRCTN98060456 ( http://www.isrctn/com )."
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 19,
    "max_score": 25
  },
  "model": "gpt-4o"
}